ABUSHealthcare · BiotechnologyThe 1 Wall Street analysts covering Arbutus Biopharma Corp. hold a median 12-month price target of $5.46 — +29.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Arbutus Biopharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ABUS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | $5.00 |
| 11 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | Chardan Capital | Maintains | Buy | $4.00 → $4.50 |
| 5 Sept 2024 | Jefferies | Maintains | Buy | — |
| 2 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 7 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | Chardan Capital | Maintains | Buy | — |
| 3 May 2024 | Chardan Capital | Reiterates | Buy | — |
| 4 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 1 Mar 2024 | Chardan Capital | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Aug 2023 | Chardan Capital | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABUS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Arbutus Biopharma Corp. returned −13.0% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 65% of US stocks
Cheaper than 33% of US stocks
Cheaper than 29% of US stocks
Cheaper than 53% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 7% of US stocks
Higher than 98% of US stocks
Higher than 96% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arbutus Biopharma Corp. has a market value of $645.3M and an enterprise value of $743.9M.
Revenue in the twelve months to 30 June 2026: $181.7M. The latest quarter shrank 90.6% year on year.
Net income over the same four quarters: $153.1M, a 84.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$24.6M.
Trailing P/E: 5.3×; forward P/E: −25.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Arbutus Biopharma Corp. employs 19 people — $9.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arbutus Biopharma Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The FDA lifted the clinical hold on Arbutus Biopharma’s Investigational New Drug application for AB-101, according to Benzinga.
Why it matters — The update concerns the regulatory status of an Arbutus clinical study and may be relevant to investors tracking the company’s hepatitis B research.
Arbutus said the FDA lifted the clinical hold on the IND application for AB-101, allowing additional clinical development in the United States. The company is evaluating next steps for the program.
Why it matters — The FDA action removes the hold and permits Arbutus to consider further U.S. clinical development of AB-101.
Seeking Alpha highlights Arbutus’s $179.1 million Moderna settlement and a 46 million-share buyback, alongside Imdusiran’s potential as an RNAi treatment aimed at a functional cure for chronic hepatitis B. The excerpt says the drug’s potential depends on positive Phase 2b/3 results.
Why it matters — The settlement and buyback are presented as supporting per-share value, while Imdusiran’s clinical results remain central to the company’s potential.
Arbutus Biopharma announced the final results of its modified Dutch auction tender offer to repurchase up to US$230 million in value of its common shares. The offer, which had a tender price range of US$5.00 to US$5.75 per share, expired on September 29, 2026.
Why it matters — A US$230 million share repurchase program is a significant capital deployment event that ABUS watchers would track to gauge shareholder returns and the company's capital allocation decisions.
Arbutus Biopharma announced preliminary results of its modified Dutch auction tender offer to purchase up to US$230 million in value of its common shares for cancellation. The offer had a tender price range of US$5.00 to US$5.75 per share and expired on September 29, 2026.
Why it matters — ABUS watchers would care because this announcement provides an update on the company's capital-return activity, which affects its outstanding share count and shareholder payout structure.
The 1 Wall Street analysts covering Arbutus Biopharma Corp. have a median 12-month price target of $5.46, with estimates ranging from $5.46 to $5.46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Arbutus Biopharma Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arbutus Biopharma Corp. 95 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Arbutus Biopharma Corp. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +29.7% from the last close, and Ticker Nerd's factor model ranks Arbutus Biopharma Corp. 95 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arbutus Biopharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.46 to $5.46 over the next 12 months.
Arbutus Biopharma Corp. returned -13.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response.
The most recent item we track (Benzinga, 22 Oct 2026): "FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study". The FDA lifted the clinical hold on Arbutus Biopharma’s Investigational New Drug application for AB-101, according to Benzinga.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.
CEO Ms. Lindsay Androski J.D., M.B.A. · 19 employees · United States · https://www.arbutusbio.com
